Integrum
Integrum receives market approval for OPRA[® in Israel]
REG
In March, Integrum entered a commercial agreement with AMI Technologies to Introduce the OPRA® Implant System to the Israeli market. With the market approval in place, AMI Technologies can now start providing OPRA® to hospitals in the region.
"There is a large need for innovative products in the region, and we appreciate the rapid regulatory approval making it possible to soon offer our life-changing treatment to Israeli amputees," says Rickard Brånemark, CEO of Integrum.
This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 29-05-2024 16:22 CET.
| Datum | 2024-05-29, kl 16:21 |
| Källa | Cision |
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.
Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.